Evidence map›Paper›PMID 33982817›Full record

ReviewCA: a cancer journal for clinicians2021

Metabolomics in cancer research and emerging applications in clinical oncology.

Daniel R Schmidt, Rutulkumar Patel, David G Kirsch, Caroline A Lewis, Matthew G Vander Heiden, Jason W Locasale

2 registry-linked trialsOpen access · diamondAbstract readReview
In one paragraph

Review in CA: a cancer journal for clinicians, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 427 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
427citing papers in PubMed, 1 pooled it
42.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05834426 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

TypeobservationalSponsorSociedad de Lucha Contra el Cáncer del EcuadorRan2023 to 2026Enrolled50ConditionsLymphoma, B-Cell, Neoplasms, Cancer, High-grade B-cell LymphomaArmsPlasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
NCT06642506 active not recruitingnot on this mapstarted 2024, after this paper: background citation

Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma.

TypeobservationalSponsorLudwig-Maximilians - University of MunichRan2024 to 2025Enrolled20ConditionsEsophagus Adenocarcinoma, Esophagus Cancer, Metabolome, Mass Spectrometry
3 · Its place in the literature

Who cites it

427 citing papers in PubMed, 1 synthesis or guideline pooled it, 646 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. NMR in biomedicine · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Correlation analysis of gut microbiota and metabolites in gastric cancer patients in plateau areas based on multi-omics technologies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  13. Prediagnostic Plasma Metabolite Profiles and Prediction of Hepatocellular Carcinoma Risk: The Multiethnic Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

367 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Daniel R SchmidtKoch Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0001-6192-0378
Rutulkumar PatelDepartment of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina.
David G KirschDepartment of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina.
Caroline A LewisWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Matthew G Vander HeidenKoch Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Jason W LocasaleDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.
Duke University · USBeth Israel Deaconess Medical Center · USDana-Farber Cancer Institute · USWhitehead Institute for Biomedical Research · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Kristin A Knouse · 1985 to 2026
$93.9M
Advancing Cancer Therapy through Ground Breaking Research in Radiation BiologyR35CA197616 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI David Guy Kirsch · 2016 to 2026
$10.7M
Institutional Career Development CoreKL2TR002542 · NCATS · HARVARD MEDICAL SCHOOL · PI BREDELLA, MIRIAM ANTOINETTE, RUTKOVE, SEWARD B. · 2018 to 2022
$8.7M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
Dietary methionine and cancerR01CA193256 · NCI · DUKE UNIVERSITY · PI LOCASALE, JASON W. · 2015 to 2023
$3.1M
Analysis of cancer cell metabolism in diverse environmental conditionsR01CA201276 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI VANDER HEIDEN, MATTHEW G., VITKUP, DENNIS · 2016 to 2020
$3.0M
Howard Hughes Medical InstituteNCATS NIH HHS KL2 TR002542NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA193256NCI NIH HHS R01 CA201276NCI NIH HHS R35 CA197616NCI NIH HHS R35 CA242379
6 · The paper itself

Abstract

Cancer has myriad effects on metabolism that include both rewiring of intracellular metabolism to enable cancer cells to proliferate inappropriately and adapt to the tumor microenvironment, and changes in normal tissue metabolism. With the recognition that fluorodeoxyglucose-positron emission tomography imaging is an important tool for the management of many cancers, other metabolites in biological samples have been in the spotlight for cancer diagnosis, monitoring, and therapy. Metabolomics is the global analysis of small molecule metabolites that like other -omics technologies can provide critical information about the cancer state that are otherwise not apparent. Here, the authors review how cancer and cancer therapies interact with metabolism at the cellular and systemic levels. An overview of metabolomics is provided with a focus on currently available technologies and how they have been applied in the clinical and translational research setting. The authors also discuss how metabolomics could be further leveraged in the future to improve the management of patients with cancer.

Indexed as

MetabolomicsBiomedical ResearchHumansMedical OncologyMolecular Targeted TherapyNeoplasmscancerintracellularmetabolismmetabolomics

Identifiers

PMID33982817
PMCPMC8298088
OpenAlexW3162293114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.